INVA
Innoviva, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
5.45
PEG
0.01
P/B
1.47
P/S
3.57
EV/EBITDA
3.21
DCF Value
$63.85
FCF Yield
13.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
78.9%
Operating Margin
-4.0%
Net Margin
65.4%
ROE
30.6%
ROA
18.9%
ROIC
-0.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $118.0M | $164.2M | $1.94 |
| FY 2025 | $425.1M | $271.2M | $3.30 |
| Q3 2025 | $107.8M | $89.9M | $1.08 |
| Q2 2025 | $100.3M | $63.7M | $0.77 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.40
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.